Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'

By: via Benzinga
Credit Suisse termed the market reaction to Bristol-Myers Squibb Co (NYSE: BMY)'s CM-214 data as overly pessimistic. The comment was ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.